# Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)

Source: https://onco.cc/trials/nct06659705/  
OnCo record `nct06659705` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by Institut Curie, now recruiting.

## Summary

Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) is a phase 2, interventional study registered as NCT06659705 by Institut Curie, with a registry enrolment figure of 35 participants, started 2025-12-02 and due to reach its primary completion in 2029-08-04. Interventions recorded: 68Ga-FAPI-46 for PET / CT scan. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC). Primary outcome: EFS: Event Free Survival. Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: INDIGO-FAPI
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06659705
- Phase: 2
- Setting: Cutting Edge Imaging for Earlier Pancreatic Cancer Diagnosis: Evaluation of Positron Emission Tomography (PET) With the Fibroblast Activation Protein Inhibitor (FAPI)
- Sponsor: Institut Curie
- Enrolled: 35

## Sources

- ClinicalTrials.gov NCT06659705: https://clinicaltrials.gov/study/NCT06659705

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06659705.json